These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 22703841)

  • 21. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.
    Soderquist R; Pletnev AA; Danilov AV; Eastman A
    Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
    Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
    Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
    Vogler M; Butterworth M; Majid A; Walewska RJ; Sun XM; Dyer MJ; Cohen GM
    Blood; 2009 Apr; 113(18):4403-13. PubMed ID: 19008458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells.
    Choi JE; Woo SM; Min KJ; Kang SH; Lee SJ; Kwon TK
    Oncol Rep; 2015 Mar; 33(3):1395-401. PubMed ID: 25592064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
    Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
    Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
    Ezzoukhry Z; Louandre C; François C; Saidak Z; Godin C; Mazière JC; Galmiche A
    Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
    Allaman-Pillet N; Oberson A; Munier F; Schorderet DF
    Ophthalmic Genet; 2013; 34(1-2):1-13. PubMed ID: 21955141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
    Reuland SN; Goldstein NB; Partyka KA; Cooper DA; Fujita M; Norris DA; Shellman YG
    PLoS One; 2011; 6(8):e24294. PubMed ID: 21897876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines.
    Foster KA; Jane EP; Premkumar DR; Morales A; Pollack IF
    J Neurooncol; 2014 Dec; 120(3):459-72. PubMed ID: 25139025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
    Subramanian A; Andronache A; Li YC; Wade M
    Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.